People who have no symptoms of Alzheimer’s disease but who have an abnormal protein believed to be a hallmark of the illness should be enrolled in clinical trials to test whether drugs can head off the disease, according to researchers. Reisa Sperling, HMS associate professor of neurology at Brigham and Women’s Hospital, is the lead author.
Trending News
Research Provides Clues to Spleen’s Role in Coronary Artery Disease
Genetic variants may drive visible changes in the spleen that contribute to heart disease
Patient Who Received Pig Kidney Becomes First To Progress to Human Kidney Transplant
Study shows xenotransplantation can serve as a bridge for patients with end-stage kidney disease
Pilots, Flight Attendants Have Greater Risk of Radiation-Related Cancer Death Than Other Professions
Findings support efforts to protect U.S. aircrews from cosmic radiation exposure